Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
DIRAS3 Antibody, ARHI Antibody, GTP-binding protein Di-Ras3 Antibody, NOEY2 Antibody, RHOI Antibody
DIRAS3 / ARHI is a member of the ras superfamily, and is expressed in normal ovarian and breast epithelial cells, but not in ovarian and breast cancers. It is an imprinted gene, with monoallelic expression of the paternal allele, which is associated with growth suppression. Thus, this gene appears to be a putative tumor suppressor gene whose function is abrogated in ovarian and breast cancers.
DIRAS3 Antibody immunohistochemistry of formalin-fixed and paraffin-embedded human brain tissue followed by peroxidase-conjugated secondary antibody and DAB staining.
DIRAS3 Antibody western blot of WiDr cell line lysates (35 ug/lane). The DIRAS3 antibody detected the DIRAS3 protein (arrow).
Western blot of lysates from HeLa cell line and human ovary tissue lysate (from left to right), using DIRAS3 Antibody. Antibody was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L (HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at 35ug per lane.
DIRAS3 Antibody flow cytometry of WiDr cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.